Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 134 matches for

A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.

© Image credit: Gates Archive/Samantha Reinders

Oxford Cancer Announces 2025 CRIS Cancer Clinical Career Fellows

Dr Rebecca Ling, a DPhil student in our Childhood Leukaemia Research Group, has been made one of two CRIS Cancer Postdoctoral Clinical Fellows for 2025.

Major investment puts UK universities at the forefront of groundbreaking lymph node research

Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.

The Kaiya Foundation to fund Leukaemia Research at University of Oxford

The Kaiya Foundation has awarded one of its first major research grants, which will fund pioneering research into the fundamental cause of a high-risk leukaemia. The grant is being made to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group, based at the University of Oxford, in the hope that their discoveries will transform treatment approaches for sufferers through personalised medicine.

New jab protects babies from serious lung infection, study shows

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.

Professor Simon Draper elected Fellow of the Academy of Medical Sciences

Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics and Kavli Institute for Nanoscience Discovery, has been elected as a Fellow to the Academy of Medical Sciences, it has been announced today.

Study shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children

Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.

Spotlight on Magdalen College Chapel for Rare Disease Day

The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.

New partnership to advance public health and life science research collaboration in West Africa

The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.

New study shows that early support for children living in marginalised communities can improve their developmental outcomes

Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.

Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies

Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.

Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection

Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.

Dr. Nicky Whiffin awarded Balfour Lecture 2025

Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford’s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.

David Cameron resumes role as chair of Advisory Council for Oxford-Harrington Rare Disease Centre (OHC)

Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.

Typhoid vaccine trial confirms sustained protection for older children

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.

New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease

A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.

Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus

Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.

New discovery renews hope for thousands with neurodevelopment disorders

A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Most NDDs are thought to be genetic and caused by changes to DNA, however, to date, around 60% of individuals with these conditions do not know the specific DNA change that causes their disorder.

New trial launches for two-in-one vaccine to prevent RSV and hMPV

Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.

Research shows early life immunity increases HIV cure/remission in male infants

New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.

GOSH Charity co-funds two data-driven projects to advance research into childhood cancers

Great Ormond Street Hospital (GOSH) Charity has joined forces with Cancer Research UK (CRUK) to co-fund two projects that will use data science to advance research into childhood cancers.

Load More

Similar stories